Columbus
Columbus BioTech, Clarametyx Biosciences, raises $33 million Series A
Clarametyx Biosciences, a Columbus-based BioTech startup, has raised a $33 million Series A round to advance its cutting-edge anti-biofilm biologics for combating serious bacterial infections. The company, founded in 2020, specializes in developing targeted, immune-empowering biologic therapies to address persistent infections linked to biofilms. Also announced was a partnership with